



IBA and the Beaumont Hospital's Cancer Institute in Royal Oak, Michigan announce partnership to develop the next generation proton therapy delivery technique.

Louvain-la-Neuve, Belgium, September 25th 2017 - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, is pleased to announce the research agreement with **Beaumont's Proton Therapy Center** to develop the next generation proton therapy delivery technique called scanned proton arc therapy (SPArc).

Proton arc therapy has the possibility to further improve the quality of the treatment by enhancing the dose conformity at the tumor level while reducing the total dose received by the patient. By better shaping the tumor dose it can further reduce dose to critical organs. In addition, arc therapy technique increases the robustness of the treatment plan, and may further improve the adoption of dose escalation and hypo-fractionation. This agreement is the first step in a long-standing partnership started several years ago.

Craig Stevens, M.D., Ph.D., Chairman, Radiation Oncology, Beaumont Health, commented: "Beaumont Hospital has been leading the research in radiotherapy for decades, and we are proud and eager to start working on such an innovative project with IBA. The level of expertise combined will bring proton therapy to the next level. Proton arc therapy has been contemplated for some time, and recent improvements in beam quality and delivery are enabling us to develop this clinically viable product. Proton SPARC therapy should allow us to improve dose conformity at the tumor, while further reducing dose to surrounding healthy tissue without the need for cumbersome and expensive beam shaping systems."

Nicolas Bronchart, Executive Vice President, Research & Development Proton Therapy, added: "IBA is once again pushing the limit of proton therapy and together with Beaumont's Proton Therapy Center we will bring a technology that could offer further benefits for patients. The initial development will take place on our compact IMPT* system, the Proteus@ONE, but IBA's strategy has always been to offer break-through advancements to our entire product line. IBA's proton therapy systems are built on the most versatile platform allowing for future upgrades and making IBA a future proof choice."

ENDS

* Intensity Modulated Proton Therapy



About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the Pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: <http://www.iba-worldwide.com>

*Proteus@ONE is the brand name of a configuration of the Proteus@235 in the US and Europe and a certified product in Japan.

About Beaumont Health

Beaumont Health is Michigan's largest health care system (based on inpatient admissions and net patient revenue) formed in 2014 to provide patients with compassionate, extraordinary care, no matter where they live in Southeast Michigan. With eight hospitals, 168 health centers, nearly 5,000 physicians and 35,000 employees, Beaumont Health contributes to the health and well-being of residents throughout southeast Michigan and beyond.

For further information, please contact:

IBA

Aymeric Harmant

Global Marketing Director

+32 10 203 796

global.marketing@iba-group.com

Thomas Ralet

Vice-President Corporate Communication

+32 10 475 890

communication@iba-group.com